Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

2 de septiembre de 2026 actualizado por: Clifton Mo, MD, Dana-Farber Cancer Institute

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (NDMM)

The purpose of the study is to determine the best treatment approach based on the risk profile of the cancer cells and on how the disease responds to treatment. This is a randomized research study evaluating treatment for transplant-eligible participants with newly diagnosed multiple myeloma (NDMM). Induction therapy in this study includes the drugs isatuximab, iberdomide, bortezomib, and dexamethasone. After induction therapy, participants will receive consolidation and maintenance therapy that is adapted based on their risk profile and response to treatment.

The research study procedures include: screening for eligibility, study visits, blood and bone marrow tests, disease assessments, treatment with study drugs, and follow-up visits.

It is expected that about 720 participants will take part in this study.

Descripción general del estudio

Descripción detallada

This is a Phase III, open-label, multicenter randomized research study designed to evaluate different treatment strategies for people with multiple myeloma. The study will look at how often participants achieve MRD (measurable residual disease)-negative status after maintenance therapy, compare different consolidation approaches, and assess long-term outcomes. Participants who are eligible will be assigned to study groups based on their cytogenetic risk and how their disease responds to induction therapy.

All participants will first receive induction treatment with isatuximab, iberdomide, bortezomib, and dexamethasone for 8 cycles. After induction, participants with standard-risk disease who are MRD-negative will continue to maintenance treatment with isatuximab and iberdomide for up to 36 cycles. After that, depending on their MRD status, they may continue on iberdomide alone or remain on the combination treatment. Participants with high-risk cytogenetics and those who remain MRD-positive after completion of induction will be randomized to receive either high-dose melphalan followed by autologous stem cell transplant or eight cycles of linvoseltamab consolidation, followed by maintenance isatuximab and iberdomide until progression of disease. Participants who are deemed medically ineligible for HDM-ASCT (after enrollment but before randomization) and those with indeterminate MRD status after induction may receive maintenance treatment with isatuximab, iberdomide, and bortezomib in lieu of randomization. The study also includes biomarker testing and participant-reported outcome assessments.

The research study procedures include screening for eligibility, clinic visits, blood tests, urine tests, computed tomography (CT) scans, bone marrow sample collection and biobanking, MRD testing, stem cell collection, skeletal survey or positive emission tomography (PET) scans, and electrocardiograms.

The study drugs include melphalan, bortezomib, isatuximab, and dexamethasone, which are approved by the FDA for the initial treatment of multiple myeloma. Linvoseltamab is approved by the FDA for multiple myeloma that has returned after at least four prior lines of treatment. Iberdomide is approved by the FDA for multiple myeloma that has returned after at least one prior line of treatment.

The study also includes an injector device, referred to as the On Body Delivery System (OBDS), also called Isatuximab subcutaneous Wearable Injection System. OBDS is a sterile, single-use, disposable, elastomeric, user-filled medical device, which includes an on-body delivery device designed for subcutaneous delivery of a defined volume of drug product and an integrated drug product syringe transfer base.

It is expected that about 720 people will take part in this research study.

Sanofi Pharmaceuticals, is supporting this research study by providing isatuximab, Celgene, a subsidiary of Bristol-Myers Squibb, is providing, iberdomide, and Regeneron is providing linvoseltamab. Study drugs are free of charge and all sponsors are providing some funding for the study.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

720

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Dana-Farber Cancer Institute
        • Contacto:
        • Investigador principal:
          • Clifton C. Mo, MD
      • Boston, Massachusetts, Estados Unidos, 02115
        • Brigham and Women's Hospital
        • Contacto:
      • Boston, Massachusetts, Estados Unidos, 02115
        • Beth Israel Deaconess Medical Center (Bidmc)
        • Contacto:
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • N- NDMM based on IMWG criteria with clonal bone marrow plasma cells ≥10% or biopsy proven bony or extramedullary disease/plasmacytoma (EMD) with any one or more CRAB-features or myeloma defining events (Rajkumar, 2024) (See Appendix E)
  • - Age 18 - 75 years. (Patients aged 71-75 years who are deemed transplant-eligible by investigator may be enrolled after discussion with and approval from the Sponsor - Investigator)
  • - Eligible for HDM-ASCT, at time of registration per investigator's assessment, and willing to defer HDM-ASCT if in Cohort 1 or be randomized to HDM-ASCT vs. linvoseltamab if in Cohort 2 (Cohort assignment may not be known until after induction therapy)
  • - Bone marrow analysis with cytogenetic risk status established by fluorescence in situ hybridization (FISH) and NGS with TP53 by PlasmaSEQ at screening and positive identification of B-cell Clonality (ID) conducted by Adaptive Biotechnologies clonoSEQ® assay

    • Qualified archival BMA may be submitted to Adaptive Biotechnologies clonoSEQ® assay.
    • Results from a previously performed clonoSEQ® assay as standard of care may be acceptable if they meet the requirement of B-cell clonality ID.
    • Previously performed BMA for FISH is acceptable if it can establish cytogenetic risk per Section 5.4.2 along with NGS for TP53 by PlasmaSEQ.
    • Results must be within 1 year of screening and be representative of current NDMM. Results older than one year must be approved by the Sponsor-Investigator.
  • Measurable disease defined by at least one of the following:

    • Serum protein electrophoresis (SPEP): Serum M protein ≥0.5 mg/dL
    • Urine protein electrophoresis (UPEP): Urine M protein ≥200 mg/24 hours
    • Serum free light chain (FLC) assay: involved FLC ≥10 mg/dL (≥100 mg/L) and abnormal serum FLC ratio (<0.26 or >1.65)
  • Screening laboratory evaluations meeting the following parameters:

    • Absolute neutrophil count (ANC) ≥1,000 cells/dL (1.0 × 10^9/L). Growth factor support is not permitted within 10 days [14 days for pegfilgrastim], prior to registration
    • Platelet count ≥ 75,000 cells/dL (75 x 109/L) without transfusions required during the 14 days prior to registration
    • Total Bilirubin ≤ 2 X upper limit of normal (ULN) (except patients with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
    • Aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase (ALT) (SGPT) ≤ 3.0 x ULN
    • Calculated creatinine clearance ≥30 mL/min (See Appendix B)
    • Hemoglobin ≥ 8.0 g/dl (red blood cell [RBC] transfusions are permitted)
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (see Appendix A)
  • Ability and willingness to complete HRQoL and PRO-CTCAE® assessments
  • Must be able to take antithrombotic prophylaxis
  • Sexually active IOCBP agree to use protocol-specified contraceptive methods, at least 28 days prior to starting study drug, while taking study drug, including interruptions in study drugs, and for at least 28 days after the last dose of iberdomide, 5 months after isatuximab, 6 months after linvoseltamab and bortezomib, or males (including those who have had a vasectomy), sexually active with IOCBP, agree to use protocol specified contraceptive methods while taking study drug, including interruptions in study drug and for at least 28 days after the last dose of iberdomide, 5 months after isatuximab, 6 months after linvoseltamab and bortezomib according the PPP (See Appendix G)
  • All patients (male and female with or without childbearing potential) agree to counseling according to the PPP and to abstain from donating blood products for at least 28 days after the last dose of iberdomide and semen or sperm while taking study drug and for at least 28 days after the last dose of iberdomide according to the PPP (See Appendix G) and for 3 months after the last dose of isatuximab, 6 months after the last dose of linvoseltamab and bortezomib
  • Both men and women of all races and ethnic groups are eligible for this trial.

Exclusion Criteria:

  • Prior therapy for MM. Patients may have received:

    • Corticosteroids for management of MM not exceeding the equivalent of 160 mg of dexamethasone in a 2-week period and without change in dosing requirements within 7 days prior to registration
    • Focal palliative radiation for the management of bone pain ≥ 7 days prior to registration
    • Treatment for smoldering multiple myeloma (SMM) if the prior treatment was not an anti-CD38 or anti-BCMA-based therapy:
    • Patients with a prior history of serious allergic reactions associated with thalidomide, lenalidomide, or pomalidomide should not receive iberdomide as they could be at higher risk of hypersensitivity
    • Resolution of symptoms of prior treatment to ≤ grade 1or baseline
  • Known intolerance to steroid therapy
  • Central nervous system (CNS) involvement of MM
  • History of progressive multifocal leukoencephalopathy (PML), known or suspected PML, or history of a neurocognitive condition, CNS movement disorder, history of seizure within 12 months prior to enrollment
  • Peripheral neuropathy grade ≥3, or grade 2 with pain on clinical exam during screening period
  • Prior history of malignancies, other than MM, will be excluded unless the participant has been free of the disease for ≥ 3 years, except for the following non-invasive malignancies: basal or squamous cell skin carcinoma, carcinoma in situ of the cervix, carcinoma in situ of the breast, incidental histological findings of prostate cancer (T1a or T1b using the TNM clinical staging system), or prostate cancer that is curative
  • Any medical or psychiatric illness that in the investigator's opinion would impose excessive risk or would adversely affect patient participation
  • Concurrent uncontrolled cardiovascular conditions (uncontrolled hypertension [HTN], uncontrolled arrhythmias, congestive heart failure [CHF], unstable angina, grade 3 thromboembolic event or myocardial infarction in the past 6 months)
  • Concurrent symptomatic amyloidosis or plasma cell leukemia
  • POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes)
  • Pregnant or breast feeding female or female who intends to become pregnant during the study
  • Seropositive for human immunodeficiency virus (HIV-1), chronic or active hepatitis B (defined as positive hepatitis B surface antigen [HepBSAg] or Hepatitis B core antibody [HepBcore Ab]) or hepatitis C (Hep C Ab), or acute hepatitis A; if any history of exposure to hepatitis B or C, then PCR should be negative
  • History of tuberculosis or systemic fungal disease
  • Concurrent active infection requiring therapeutic treatment
  • Lack of clonal identification by Adaptive Biotechnologies clonoSEQ® test

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Otro: Arm B (Cohort 1 Maintenance Therapy Part 1)
Participants assigned to Cohort 1 enter Arm B and receive isatuximab + iberdomide maintenance for 36 cycles. Maintenance should begin within 28 days of the last induction cycle.
Supplied by Bristol Myers Squibb/Celgene (BMS); used across induction and maintenance phases; administered orally.
Otros nombres:
  • CC-220
Device: On Body Delivery System (OBDS) - Sanofi-Aventis device used with isatuximab administration; abdominal/periumbilical single-site application with post-dose needle retraction and lock-out.
Otros nombres:
  • Sistema de inyección portátil de isatuximab sc
Supplied by Sanofi-Aventis (Sanofi); used in induction and maintenance/consolidation strategies in this protocol; administered subcutaneously (SC) in the maintenance tables provided; not administered in Arm C.
Otros nombres:
  • Sarclisa
Experimental: Arm F: Cohort 2 Randomized Consolidation and Maintenance (Linvoseltamab Strategy)
Eligible Cohort 2 participants are randomized to Arm F: linvoseltamab consolidation for 8 cycles followed by isatuximab + iberdomide maintenance until progression. The protocol explicitly identifies Arm F as the experimental arm and hypothesizes superior efficacy versus Arm E. Maintenance should begin within 2-4 weeks after the last linvoseltamab dose.
Supplied by Bristol Myers Squibb/Celgene (BMS); used across induction and maintenance phases; administered orally.
Otros nombres:
  • CC-220
Device: On Body Delivery System (OBDS) - Sanofi-Aventis device used with isatuximab administration; abdominal/periumbilical single-site application with post-dose needle retraction and lock-out.
Otros nombres:
  • Sistema de inyección portátil de isatuximab sc
Supplied by Regeneron; used in Arm F consolidation for 8 cycles before maintenance therapy.
Otros nombres:
  • REGN5458
Supplied by Sanofi-Aventis (Sanofi); used in induction and maintenance/consolidation strategies in this protocol; administered subcutaneously (SC) in the maintenance tables provided; not administered in Arm C.
Otros nombres:
  • Sarclisa
Otro: Arm A (Induction and screening)
All enrolled participants begin with Step 1 induction that consists of eight 28-day cycles before end-of-induction cohort assignment. Peripheral Blood Stem Cells (PBSC) mobilization/collection is planned after completion of 4-6 cycles of induction for participants without disease progression. End-of-induction MRD/response and cytogenetic risk status determine whether participants proceed to post-induction Cohort 1 or Cohort 2.
Supplied by Bristol Myers Squibb/Celgene (BMS); used across induction and maintenance phases; administered orally.
Otros nombres:
  • CC-220
Commercial supply; used in induction and Arm G maintenance; administered subcutaneously in Arm G on Days 1 and 15 of each 28-day cycle.
Otros nombres:
  • BORT
Commercial supply; used in induction; may be administered intravenously or orally at investigator discretion; excluded from Arm G.
Device: On Body Delivery System (OBDS) - Sanofi-Aventis device used with isatuximab administration; abdominal/periumbilical single-site application with post-dose needle retraction and lock-out.
Otros nombres:
  • Sistema de inyección portátil de isatuximab sc
Supplied by Sanofi-Aventis (Sanofi); used in induction and maintenance/consolidation strategies in this protocol; administered subcutaneously (SC) in the maintenance tables provided; not administered in Arm C.
Otros nombres:
  • Sarclisa
Otro: Arm C: Cohort 1 Maintenance Therapy (Part 2), Single-Agent Iberdomide
After completion of Arm B, participants with MRD-negative Complete Response (CR) status at Step 3 are assigned to Arm C and continue single-agent iberdomide until progression. Isatuximab is not administered in Arm C.
Supplied by Bristol Myers Squibb/Celgene (BMS); used across induction and maintenance phases; administered orally.
Otros nombres:
  • CC-220
Otro: Arm D: Cohort 1 Maintenance Therapy (Part 2), Iberdomide + Isatuximab
After completion of Arm B, participants with MRD-positive or MRD-indeterminate disease, or <VGPR (very good partial response) at Step 3 evaluation [unless Progressive Disease (PD)], continue iberdomide + isatuximab until progression.
Supplied by Bristol Myers Squibb/Celgene (BMS); used across induction and maintenance phases; administered orally.
Otros nombres:
  • CC-220
Device: On Body Delivery System (OBDS) - Sanofi-Aventis device used with isatuximab administration; abdominal/periumbilical single-site application with post-dose needle retraction and lock-out.
Otros nombres:
  • Sistema de inyección portátil de isatuximab sc
Supplied by Sanofi-Aventis (Sanofi); used in induction and maintenance/consolidation strategies in this protocol; administered subcutaneously (SC) in the maintenance tables provided; not administered in Arm C.
Otros nombres:
  • Sarclisa
Comparador activo: Arm E: Cohort 2 Randomized Consolidation and Maintenance (HDM-ASCT) Strategy
Eligible Cohort 2 participants are randomized to Arm E: High-Dose Melphalan followed by Autologous Stem Cell Transplantation (HDM-ASCT) consolidation followed by isatuximab + iberdomide maintenance until progression. The protocol identifies Arm E as the control arm and describes HDM-ASCT-based therapy as the SOC comparator for Cohort 2. Consolidation should begin preferably within 30 days, and no later than 42 days, after induction completion. Maintenance begins 60-110 days after PBSC infusion.
Supplied by Bristol Myers Squibb/Celgene (BMS); used across induction and maintenance phases; administered orally.
Otros nombres:
  • CC-220
Device: On Body Delivery System (OBDS) - Sanofi-Aventis device used with isatuximab administration; abdominal/periumbilical single-site application with post-dose needle retraction and lock-out.
Otros nombres:
  • Sistema de inyección portátil de isatuximab sc
Commercial supply; used as conditioning therapy for Arm E before PBSC infusion/ASCT; administered intravenously.
Otros nombres:
  • Mostaza con fenilalanina
  • L-PAM
  • Mostaza L-fenilalanina
  • L-sarcolisina
  • Evomela
Supplied by Sanofi-Aventis (Sanofi); used in induction and maintenance/consolidation strategies in this protocol; administered subcutaneously (SC) in the maintenance tables provided; not administered in Arm C.
Otros nombres:
  • Sarclisa
Otro: Arm G: Cohort 2 Non-randomized 3-Drug Maintenance
Participants in Cohort 2 who do not meet criteria for consolidation therapy may enter Arm G. Standard Risk (SR) MRD-indeterminate participants may also enter Arm G or, with Sponsor-Investigator approval, may be randomized in Cohort 2. Arm G is a 3-drug maintenance regimen continued in 28-day cycles until progression. The protocol explicitly states that dexamethasone is excluded from Arm G.
Supplied by Bristol Myers Squibb/Celgene (BMS); used across induction and maintenance phases; administered orally.
Otros nombres:
  • CC-220
Commercial supply; used in induction and Arm G maintenance; administered subcutaneously in Arm G on Days 1 and 15 of each 28-day cycle.
Otros nombres:
  • BORT
Device: On Body Delivery System (OBDS) - Sanofi-Aventis device used with isatuximab administration; abdominal/periumbilical single-site application with post-dose needle retraction and lock-out.
Otros nombres:
  • Sistema de inyección portátil de isatuximab sc
Supplied by Sanofi-Aventis (Sanofi); used in induction and maintenance/consolidation strategies in this protocol; administered subcutaneously (SC) in the maintenance tables provided; not administered in Arm C.
Otros nombres:
  • Sarclisa

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
3-Year Sustained Minimal Residual Disease (sMRD)-negative Complete Response (CR) Rate [Cohort 1] (Step 2)
Periodo de tiempo: Assessed after Step 2 maintenance cycle 36 (cycle duration=4 weeks), at 144 weeks/36 months.
sMRD-negative CR rate is defined as the proportion of participants who sustain MRD negativity at a minimum 10^-5 sensitivity assessed by next-generation sequencing (NGS) during the time of confirmed CR or better response per the International Myeloma Working Group Uniform Response Criteria (IMWG-URC).
Assessed after Step 2 maintenance cycle 36 (cycle duration=4 weeks), at 144 weeks/36 months.
1-Year MRD-Negative CR Rate [Cohort 2] (Step 2)
Periodo de tiempo: Assessed 1-year after Step 2 consolidation randomization.
MRD-negative CR rate is defined as the proportion of participants who achieve MRD negativity at a minimum 10^-5 sensitivity assessed by NGS during the time of confirmed CR or better response per IMWG-URC.
Assessed 1-year after Step 2 consolidation randomization.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
1-Year MRD-Negative CR Rate [Cohort 1] (Step 3)
Periodo de tiempo: Assessed after Step 3 maintenance cycle 12 (cycle duration=4 weeks), at 48 weeks/12 months.
MRD-negative CR rate is defined as the proportion of participants who sustain MRD negativity or convert to MRD negativity at a minimum 10^-5 sensitivity assessed by NGS during the time of confirmed CR or better response per IMWG-URC.
Assessed after Step 3 maintenance cycle 12 (cycle duration=4 weeks), at 48 weeks/12 months.
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Role Functioning (RF) Subscale Response [Cohort 1] (Step 2)
Periodo de tiempo: Assessed day 1 every 3 cycles during Step 2 maintenance cycles 1-36 (cycle duration=4 weeks), up to 144 weeks/36 months.
EORTC QLQ-C30 RF subscale response is defined as an increase of ≥15 points in the RF score from Step 2 baseline, based on established guidelines. The RF subscale consists of 2 items scored on a 4-point Likert scale ("Not at all" to "Very much"). Raw scores are reverse scored and linearly transformed to a 0-100 scale then averaged, with higher scores indicating better functioning. Number of responses over Step 2 maintenance treatment is summed by participant.
Assessed day 1 every 3 cycles during Step 2 maintenance cycles 1-36 (cycle duration=4 weeks), up to 144 weeks/36 months.
EORTC QLQ-C30 RF Subscale Response [Cohort 1] (Step 3)
Periodo de tiempo: Assessed day 1 every 2 cycles during Step 3 maintenance cycles 1-12 (cycle duration=4 weeks), up to 48 weeks/12 months.
EORTC QLQ-C30 RF subscale response is defined as an increase of ≥15 points in the RF score from Step 3 baseline, based on established guidelines. The RF subscale consists of 2 items scored on a 4-point Likert scale ("Not at all" to "Very much"). Raw scores are reverse scored and linearly transformed to a 0-100 scale then averaged, with higher scores indicating better functioning. Number of responses over Step 3 maintenance treatment is summed by participant.
Assessed day 1 every 2 cycles during Step 3 maintenance cycles 1-12 (cycle duration=4 weeks), up to 48 weeks/12 months.
Median Progression-Free Survival (PFS) [Cohort 1] (Step 2)
Periodo de tiempo: Assessed day 1 of each cycle during Step 2 maintenance cycles 1-36 (cycle duration=4 weeks) on treatment, up to 144 weeks/36 months. In long-term follow-up, assessed every 3 months, up to 88 months after Step 2 maintenance registration.
PFS based on Kaplan-Meier method is defined as the time from maintenance Step 2 registration until the earlier of disease progression (PD) per IMWG-URC or death due to any cause (events). Deaths occurring beyond 6 months from the date last known progression-free are not counted as events and instead censored at the date of last disease evaluation. Patients who start Non-Protocol Therapy (NPT) prior to PD are censored at the date of NPT. Patients alive who did not experience PD or start NPT are censored at the date of last disease evaluation.
Assessed day 1 of each cycle during Step 2 maintenance cycles 1-36 (cycle duration=4 weeks) on treatment, up to 144 weeks/36 months. In long-term follow-up, assessed every 3 months, up to 88 months after Step 2 maintenance registration.
Median Progression-Free Survival (PFS) [Cohort 1] (Step 3)
Periodo de tiempo: Assessed day 1 of each cycle during Step 3 maintenance cycle 1 and beyond (cycle duration=4 weeks) on treatment. In long-term follow-up, assessed every 3 months, up to 52 months after Step 3 registration.
PFS based on Kaplan-Meier method is defined as the time from maintenance Step 3 registration until the earlier of PD per IMWG-URC or death due to any cause (events). Deaths occurring beyond 6 months from the date last known progression-free are not counted as events and instead censored at the date of last disease evaluation. Patients who start NPT prior to PD are censored at the date of NPT. Patients alive who did not experience PD or start NPT are censored at the date of last disease evaluation.
Assessed day 1 of each cycle during Step 3 maintenance cycle 1 and beyond (cycle duration=4 weeks) on treatment. In long-term follow-up, assessed every 3 months, up to 52 months after Step 3 registration.
Best Response [Cohort 1] (Step 2)
Periodo de tiempo: Assessed at day 1 of each cycle over 36 cycles of Step 2 maintenance treatment (cycle duration=4 weeks), up to 144 weeks/36 months.
Frequency of best response over Step 2 maintenance including stringent complete response(sCR), CR, very good partial response (VGPR), partial response (PR), minimal response (MR), stable disease (SD) or progressive disease (PD) per IMWG-URC.
Assessed at day 1 of each cycle over 36 cycles of Step 2 maintenance treatment (cycle duration=4 weeks), up to 144 weeks/36 months.
Best Response [Cohort 1] (Step 3)
Periodo de tiempo: Assessed day 1 of every cycle of Step 3 maintenance treatment and in long term follow-up every 3 months, up to approximately 52 months.
Frequency of best response over Step 3 maintenance including sCR, CR, VGPR, PR, MR, SD or PD per IMWG-URC.
Assessed day 1 of every cycle of Step 3 maintenance treatment and in long term follow-up every 3 months, up to approximately 52 months.
Serious Adverse Events (SAE) Rate [Cohort 1] (Step 2)
Periodo de tiempo: Assessed continuously over 36 cycles of Step 2 maintenance treatment (cycle duration=4 weeks), up to 144 weeks/36 months + 30 days.
SAE rate is defined as the proportion of participants who experience any untoward medical occurrence at any dose that results in death, is life-threatening (i.e., the patient was at risk of death at the time of the event, not hypothetically), requires inpatient hospitalization or prolongation of existing hospitalization (excluding planned hospitalizations), results in persistent or significant disability or incapacity (defined as substantial disruption of normal life functions), is a congenital anomaly or birth defect, or is considered a medically important event.
Assessed continuously over 36 cycles of Step 2 maintenance treatment (cycle duration=4 weeks), up to 144 weeks/36 months + 30 days.
SAE Rate [Cohort 1] (Step 3)
Periodo de tiempo: Assessed continuously over Step 2 maintenance treatment (cycle duration=4 weeks), up to approximately 52 months + 30 days.
SAE rate is defined as the proportion of participants who experience any untoward medical occurrence at any dose that results in death, is life-threatening (i.e., the patient was at risk of death at the time of the event, not hypothetically), requires inpatient hospitalization or prolongation of existing hospitalization (excluding planned hospitalizations), results in persistent or significant disability or incapacity (defined as substantial disruption of normal life functions), is a congenital anomaly or birth defect, or is considered a medically important event.
Assessed continuously over Step 2 maintenance treatment (cycle duration=4 weeks), up to approximately 52 months + 30 days.
Grade 3 or Higher Non-Hematologic (NH) Treatment-Related Adverse Event (TRAE) Rate [Cohort 1] (Step 2)
Periodo de tiempo: Assessed continuously over 36 cycles of Step 2 maintenance treatment (cycle duration=4 weeks), up to 144 weeks/36 months + 30 days.
Grade 3 or higher NH TRAE rate is defined as the proportion of participants who experience a grade 3 or higher NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 maintenance therapy.
Assessed continuously over 36 cycles of Step 2 maintenance treatment (cycle duration=4 weeks), up to 144 weeks/36 months + 30 days.
1-Year Grade 3 or Higher Hematologic TRAE Rate [Cohort 1] (Step 3)
Periodo de tiempo: Assessed continuously over 36 cycles of Step 2 maintenance treatment (cycle duration=4 weeks), up to 144 weeks/36 months + 30 days.
Grade 3 or higher hematologic TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 3 maintenance therapy.
Assessed continuously over 36 cycles of Step 2 maintenance treatment (cycle duration=4 weeks), up to 144 weeks/36 months + 30 days.
Grade 3 or Higher TRAE Rate [Cohort 1] (Step 2)
Periodo de tiempo: Assessed continuously over 36 cycles of Step 2 maintenance treatment (cycle duration=4 weeks), up to 144 weeks/36 months + 30 days.
Grade 3 or higher TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic or non-hematologic adverse event based on CTCAEv5 with a treatment attribution of possible, probable or definite over maintenance therapy.
Assessed continuously over 36 cycles of Step 2 maintenance treatment (cycle duration=4 weeks), up to 144 weeks/36 months + 30 days.
1-Year Grade 3 or Higher Non-Hematologic (NH) Treatment-Related Adverse Event (TRAE) Rate [Cohort 1] (Step 3)
Periodo de tiempo: Assessed continuously over 12 cycles of Step 3 maintenance (cycle duration=4 weeks), up to 1 year + 30 days.
Grade 3 or higher NH TRAE rate is defined as the proportion of participants who experience a grade 3 or higher NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 3 maintenance therapy.
Assessed continuously over 12 cycles of Step 3 maintenance (cycle duration=4 weeks), up to 1 year + 30 days.
1-Year Grade 3 or Higher Hematologic TRAE Rate [Cohort 1] (Step 3)
Periodo de tiempo: Assessed continuously over 12 cycles of Step 3 maintenance (cycle duration=4 weeks), up to 1 year + 30 days.
Grade 3 or higher hematologic TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 3 maintenance therapy.
Assessed continuously over 12 cycles of Step 3 maintenance (cycle duration=4 weeks), up to 1 year + 30 days.
1-Year Grade 3 or Higher TRAE Rate [Cohort 1] (Step 3)
Periodo de tiempo: Assessed continuously over 12 cycles of Step 3 maintenance (cycle duration=4 weeks), up to 1 year + 30 days.
Grade 3 or higher hematologic TRAE rate is defined as the proportion of participants who experience a grade 3 or higher NH or hematologic AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 3 maintenance therapy.
Assessed continuously over 12 cycles of Step 3 maintenance (cycle duration=4 weeks), up to 1 year + 30 days.
1-Year EORTC QLQ-C30 RF Subscale Response [Cohort 2] (Step 2)
Periodo de tiempo: Assessed day 1 every 2 cycles or every 2 months on Step 2 treatment, up to 1 year.
EORTC QLQ-C30 RF subscale response is defined as an increase of ≥15 points in the RF score from Step 2 baseline, based on established guidelines. The RF subscale consists of 2 items scored on a 4-point Likert scale ("Not at all" to "Very much"). Raw scores are reverse scored and linearly transformed to a 0-100 scale then averaged, with higher scores indicating better functioning. Number of responses over Step 2 consolidation and maintenance treatment, up to 1 year, are summed by participant.
Assessed day 1 every 2 cycles or every 2 months on Step 2 treatment, up to 1 year.
Median PFS [Cohort 2] (Step 2)
Periodo de tiempo: Assessed day 1 of each cycle or every month during Step 2 treatment. In long-term follow-up, assessed every 3 months, up to 88 months after Step 2 randomization.
PFS based on Kaplan-Meier method is defined as the time from Step 2 randomization until the earlier of PD per IMWG-URC or death due to any cause (events). Deaths occurring beyond 6 months from the date last known progression-free are not counted as events and instead censored at the date of last disease evaluation. Patients who start NPT prior to PD are censored at the date of NPT. Patients alive who did not experience PD or start NPT are censored at the date of last disease evaluation.
Assessed day 1 of each cycle or every month during Step 2 treatment. In long-term follow-up, assessed every 3 months, up to 88 months after Step 2 randomization.
Maintenance Best Response [Cohort 2] (Step 2)
Periodo de tiempo: Assessed at day 1 of each cycle over Step 2 maintenance treatment (cycle duration=4 weeks), up to 80 months.
Frequency of best response over Step 2 maintenance including sCR, CR, VGPR, PR, MR, SD or PD per IMWG-URC.
Assessed at day 1 of each cycle over Step 2 maintenance treatment (cycle duration=4 weeks), up to 80 months.
1-Year Best Response [Cohort 2] (Step 2)
Periodo de tiempo: Assessed at day 1 of each cycle or every month over Step 2 treatment, up to 1 year.
Frequency of best response over Step 2 consolidation and maintenance treatment up, to 1-year, including sCR, CR, VGPR, PR, MR, SD or PD per IMWG-URC.
Assessed at day 1 of each cycle or every month over Step 2 treatment, up to 1 year.
Consolidation Best Response [Cohort 2] (Step 2)
Periodo de tiempo: Assessed day 1 over 8 cycles of Step 2 consolidation (cycle duration=4 weeks), up to 32 weeks/8 months; or from start of high-dose melphalan (HDM) day -2, though day 0 peripheral blood stem cell (PBSC) infusion up to maintenance start prior to day 110.
Frequency of best response over Step 2 consolidation treatment up including sCR, CR, VGPR, PR, MR, SD or PD per IMWG-URC.
Assessed day 1 over 8 cycles of Step 2 consolidation (cycle duration=4 weeks), up to 32 weeks/8 months; or from start of high-dose melphalan (HDM) day -2, though day 0 peripheral blood stem cell (PBSC) infusion up to maintenance start prior to day 110.
Maintenance SAE Rate [Cohort 2] (Step 2)
Periodo de tiempo: Assessed continuously over Step 2 maintenance treatment, up to 80 months + 30 days.
SAE rate is defined as the proportion of participants who experience any untoward medical occurrence at any dose that results in death, is life-threatening (i.e., the patient was at risk of death at the time of the event, not hypothetically), requires inpatient hospitalization or prolongation of existing hospitalization (excluding planned hospitalizations), results in persistent or significant disability or incapacity (defined as substantial disruption of normal life functions), is a congenital anomaly or birth defect, or is considered a medically important event over Step 2 maintenance treatment.
Assessed continuously over Step 2 maintenance treatment, up to 80 months + 30 days.
Consolidation SAE Rate [Cohort 2] (Step 2)
Periodo de tiempo: Assessed continuously over 8 Step 2 consolidation cycles (4 weeks each), up to 32 weeks/8 months +30 days; or from high-dose melphalan (HDM) day -2 through day 0 PBSC infusion to maintenance start before day 110 +30 days.
SAE rate is defined as the proportion of participants who experience any untoward medical occurrence at any dose that results in death, is life-threatening (i.e., the patient was at risk of death at the time of the event, not hypothetically), requires inpatient hospitalization or prolongation of existing hospitalization (excluding planned hospitalizations), results in persistent or significant disability or incapacity (defined as substantial disruption of normal life functions), is a congenital anomaly or birth defect, or is considered a medically important event over Step 2 consolidation.
Assessed continuously over 8 Step 2 consolidation cycles (4 weeks each), up to 32 weeks/8 months +30 days; or from high-dose melphalan (HDM) day -2 through day 0 PBSC infusion to maintenance start before day 110 +30 days.
Maintenance Grade 3 or Higher NH TRAE Rate [Cohort 2] (Step 2)
Periodo de tiempo: Assessed continuously over Step 2 maintenance treatment, up to 80 months + 30 days.
Grade 3 or higher NH TRAE rate is defined as the proportion of participants who experience a grade 3 or higher NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 maintenance therapy.
Assessed continuously over Step 2 maintenance treatment, up to 80 months + 30 days.
1-Year Grade 3 or Higher NH TRAE Rate [Cohort 2] (Step 2)
Periodo de tiempo: Assessed continuously over Step 2 consolidation and maintenance treatment, up to 1-year + 30 days.
Grade 3 or higher NH TRAE rate is defined as the proportion of participants who experience a grade 3 or higher NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 consolidation and maintenance therapy, up to 1-year.
Assessed continuously over Step 2 consolidation and maintenance treatment, up to 1-year + 30 days.
Maintenance Grade 3 or Higher Hematologic TRAE Rate [Cohort 2] (Step 2)
Periodo de tiempo: Assessed continuously over Step 2 maintenance treatment, up to 80 months + 30 days.
Grade 3 or higher hematologic TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 maintenance therapy.
Assessed continuously over Step 2 maintenance treatment, up to 80 months + 30 days.
1-Year Grade 3 or Higher Hematologic TRAE Rate [Cohort 2] (Step 2)
Periodo de tiempo: Assessed continuously over Step 2 consolidation and maintenance treatment, up to 1-year + 30 days.
Grade 3 or higher hematologic TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 consolidation and maintenance therapy, up to 1- year + 30 days.
Assessed continuously over Step 2 consolidation and maintenance treatment, up to 1-year + 30 days.
Maintenance Grade 3 or Higher TRAE Rate [Cohort 2] (Step 2)
Periodo de tiempo: Assessed continuously over Step 2 maintenance treatment, up to 80 months + 30 days.
Grade 3 or higher TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic or NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 maintenance therapy.
Assessed continuously over Step 2 maintenance treatment, up to 80 months + 30 days.
1-Year Grade 3 or Higher TRAE Rate [Cohort 2] (Step 2)
Periodo de tiempo: Assessed continuously over Step 2 consolidation and maintenance treatment, up to 1-year + 30 days.
Grade 3 or higher TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic or NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 consolidation and maintenance therapy, up to 1-year + 30 days.
Assessed continuously over Step 2 consolidation and maintenance treatment, up to 1-year + 30 days.
Consolidation Grade 3 or Higher NH TRAE Rate [Cohort 2] (Step 2)
Periodo de tiempo: Assessed continuously over 8 Step 2 consolidation cycles (4 weeks each), up to 32 weeks/8 months +30 days; or from high-dose melphalan (HDM) day -2 through day 0 PBSC infusion to maintenance start before day 110 +30 days.
Grade 3 or higher NH TRAE rate is defined as the proportion of participants who experience a grade 3 or higher NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 consolidation.
Assessed continuously over 8 Step 2 consolidation cycles (4 weeks each), up to 32 weeks/8 months +30 days; or from high-dose melphalan (HDM) day -2 through day 0 PBSC infusion to maintenance start before day 110 +30 days.
Consolidation Grade 3 or Higher Hematologic TRAE Rate [Cohort 2] (Step 2)
Periodo de tiempo: Assessed continuously over 8 Step 2 consolidation cycles (4 weeks each), up to 32 weeks/8 months +30 days; or from high-dose melphalan (HDM) day -2 through day 0 PBSC infusion to maintenance start before day 110 +30 days.
Grade 3 or higher hematologic TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 consolidation.
Assessed continuously over 8 Step 2 consolidation cycles (4 weeks each), up to 32 weeks/8 months +30 days; or from high-dose melphalan (HDM) day -2 through day 0 PBSC infusion to maintenance start before day 110 +30 days.
Consolidation Grade 3 or Higher TRAE Rate [Cohort 2] (Step 2)
Periodo de tiempo: Assessed continuously over 8 Step 2 consolidation cycles (4 weeks each), up to 32 weeks/8 months +30 days; or from high-dose melphalan (HDM) day -2 through day 0 PBSC infusion to maintenance start before day 110 +30 days.
Grade 3 or higher TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic or NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 consolidation.
Assessed continuously over 8 Step 2 consolidation cycles (4 weeks each), up to 32 weeks/8 months +30 days; or from high-dose melphalan (HDM) day -2 through day 0 PBSC infusion to maintenance start before day 110 +30 days.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Clifton C. Mo, MD, Dana-Farber Cancer Institute

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

24 de agosto de 2026

Finalización primaria (Estimado)

1 de octubre de 2033

Finalización del estudio (Estimado)

1 de marzo de 2038

Fechas de registro del estudio

Enviado por primera vez

28 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

28 de mayo de 2026

Publicado por primera vez (Actual)

3 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

8 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The Harvard Cancer Consortium encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Marco de tiempo para compartir IPD

Data can be shared no earlier than 1 year following the date of publication

Criterios de acceso compartido de IPD

Contact the Belfer office for Dana -Farber Innovations (BODFI) at innovations@dfci.harvard.edu

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir